Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $8.6 million.

  • Roivant Sciences' Change in Accured Expenses rose 14398.42% to $8.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$23.4 million, marking a year-over-year increase of 5478.31%. This contributed to the annual value of -$10.1 million for FY2025, which is 12508.09% down from last year.
  • As of Q4 2025, Roivant Sciences' Change in Accured Expenses stood at $8.6 million, which was up 14398.42% from $12.5 million recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Change in Accured Expenses peaked at $37.6 million during Q3 2023, and registered a low of -$50.0 million during Q2 2023.
  • For the 5-year period, Roivant Sciences' Change in Accured Expenses averaged around -$450800.0, with its median value being $5.7 million (2022).
  • In the last 5 years, Roivant Sciences' Change in Accured Expenses skyrocketed by 28176.06% in 2021 and then crashed by 37683.27% in 2023.
  • Quarter analysis of 5 years shows Roivant Sciences' Change in Accured Expenses stood at $35.6 million in 2021, then tumbled by 83.97% to $5.7 million in 2022, then plummeted by 376.83% to -$15.8 million in 2023, then dropped by 23.58% to -$19.5 million in 2024, then surged by 143.98% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q4 2025, $12.5 million for Q3 2025, and -$25.0 million during Q2 2025.